#None #Pomerantz LLP #Ultragenyx #RARE

Investor Alert: Investigation into Ultragenyx Pharmaceutical Over Securities Claims

On January 29, 2026, the Pomerantz Law Firm announced an investigation aimed at uncovering possible securities fraud involving Ultragenyx Pharmaceutical Inc. The inquiry is particularly focused on allegations surrounding the company’s performance and whether its executives participated in wrongful business practices. Investors who acquired stocks in Ultragenyx are being encouraged to reach out if they wish to participate in this investigation.

This news arrives in the wake of Ultragenyx's announcement regarding the outcomes of two Phase 3 clinical trials for setrusumab, a medication aimed at addressing conditions that affect bone metabolism. Unfortunately, these trials did not meet their primary objectives: neither was able to show a statistically significant reduction in annualized clinical fracture rates when compared to both placebo and existing treatments like bisphosphonates.

Despite the setbacks in primary endpoints, both trials were able to achieve their secondary goals, demonstrating significant improvements in bone mineral density. The results pointed to a strong potential in enhancing patient outcomes through these secondary metrics, yet the primary failures raised critical questions regarding the product's viability on the market.

The fallout from these disappointing results was immediate. On December 29, 2025, on the day of the announcements, Ultragenyx's stock suffered a dramatic drop, plummeting by $2.02, or approximately 87.64%, landing at a mere $0.28 per share. This steep decline has understandably left investors feeling anxious and prompted the investigation by Pomerantz LLP, a respected firm known for its expertise in corporate, securities, and antitrust class litigation.

Founded over 85 years ago by Abraham L. Pomerantz, widely regarded as a pioneer in the area of securities class actions, Pomerantz LLP has an established track record in representing the interests of victims affected by corporate misconduct. The firm has historically secured substantial damages for its clients and is currently poised to do the same for Ultragenyx investors seeking restitution.

If you are a current or former shareholder of Ultragenyx Pharmaceutical Inc. and believe you may have been misled, it is important to contact Pomerantz LLP as soon as possible. Legal representatives, including attorney Danielle Peyton, can provide guidance and facilitate participation in the class action investigation. Interested investors can reach her directly via email or phone, as indicated in the firm’s announcement.

As the investigation unfolds, it underscores the importance of transparency in financial disclosures and the responsibilities company executives have toward their shareholders. For Ultragenyx and those who invested, this could potentially be a critical juncture. Investors should stay informed and proactive as new information becomes available, understanding that each development could significantly impact their financial interests.

Contact Information

For those wishing to join the legal proceedings or seeking further information on the investigation, please contact Danielle Peyton at Pomerantz LLP. You might find this situation serves as a reminder of the volatile nature of investment environments and the necessity of vigilance in monitoring corporate actions and public disclosures.

Stay tuned for more updates as the situation progresses, as well as any major announcements from Ultragenyx regarding their ongoing trials and business directions going forward. Investors should remain alert and consider their options carefully in light of these recent developments.